Magazine Article | November 1, 2022

Companies To Watch: iTolerance

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Dedicated to curing diabetes and other conditions by inducing local immune tolerance in implantation

iTolerance is in early development of a drug treatment that would eliminate the need for immunosuppression in implantation of islet cells to secrete insulin in patients with Type 1 diabetes. The treatment, coded iTOL- 100, suppresses activated T cells that would otherwise cause immune rejection of the transplanted cells. It does so by binding to the Fas receptor (FasR) on the activated T cells, causing them to die by apoptosis. iTolerance has completed mouse and non-human primate testing on the treatment with positive results. Other organ transplant programs, such as for the liver, are underway or under consideration.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader